Fulminant hepatitis B reactivation leading to liver transplantation in a patient with chronic hepatitis C treated with simeprevir and sofosbuvir: a case report

Journal of Medical Case Reports

Charles S. Landis²  Jason Harper²  Matthew M. Yeh³  Nina H. Kim¹  Alexander R. Ende² 

[1] Department of Medicine, Division of Infectious Disease, University of Washington, 1959 Northeast Pacific Street, Seattle 98195, WA, USA;Department of Medicine, Division of Gastroenterology and Hepatology, University of Washington, 1959 Northeast Pacific Street, Seattle 98195, WA, USA;Department of Pathology, University of Washington, 1959 Northeast Pacific Street, Seattle 98195, WA, USA

关键词: Hepatitis B reactivation;    Liver transplant;    Fulminant liver failure;    Sofosbuvir;    Simeprevir;    Hepatitis C;    Hepatitis B;   

Others  :  1231410
DOI  :  10.1186/s13256-015-0630-8

 received in 2014-12-16, accepted in 2015-05-29,  发布年份 2015

【 摘 要 】

Introduction

Hepatitis B and C coinfection is commonly seen in clinical practice. In coinfected individuals, high levels of hepatitis C viremia are often associated with low levels of serum hepatitis B DNA. Hepatitis B reactivation in hepatitis C-infected patients treated with pegylated interferon and ribavirin has been reported, but severe or fulminant reactivation is uncommon. Hepatitis C treatment-associated hepatitis B reactivation in patients with chronic hepatitis C and isolated core antibody has not been reported previously.

Case presentation

A 59-year-old white woman with chronic hepatitis C genotype 1B and isolated hepatitis B core antibody initiated treatment with simeprevir, sofosbuvir, and ribavirin for treatment of chronic hepatitis C. She responded very well to treatment initially with near normalization of aminotransferases and hepatitis C viral load suppressed to below the level of quantification after 4 weeks of treatment. At week 11 of a planned 12-week course, she developed fulminant hepatic failure due to hepatitis B reactivation and ultimately required liver transplantation. Fortunately, her posttransplant clinical course was unremarkable.

Conclusions

This is the first report of hepatitis B reactivation in a patient with isolated hepatitis B core antibody leading to fulminant hepatic failure and liver transplantation after initiation of treatment with sofosbuvir, simeprevir, and ribavirin for hepatitis C. This case raises the concern for the risk of severe hepatitis B reactivation in hepatitis B and C-coinfected patients or chronic hepatitis C-infected patients with isolated hepatitis B core antibody treated with direct-acting antiviral drugs for hepatitis C.

【 授权许可】

   
2015 Ende et al.

【 图 表 】

Fig. 1.

【 参考文献 】

• [1]Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A et al.. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014; 384:1756-65.
• [2]Bini EJ, Perumalswami PV. Hepatitis B virus infection among American patients with chronic hepatitis C virus infection: prevalence, racial/ethnic differences, and viral interactions. Hepatology. 2010; 51:759-66.
• [3]Chu CJ, Lee SD. Hepatitis B virus/hepatitis C virus coinfection: epidemiology, clinical features, viral interactions and treatment. J Gastroenterol Hepatol. 2008; 23:512-20.
• [4]Saravanan S, Velu V, Nandakumar S, Madhavan V, Shanmugasundaram U, Murugavel KG et al.. Hepatitis B virus and hepatitis C virus dual infection among patients with chronic liver disease. J Microbiol Immunol Infect. 2009; 42:122-8.
• [5]Tyson GL, Kramer JR, Duan Z, Davila JA, Richardson PA, El-Serag HB. Prevalence and predictors of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients. Hepatology. 2013; 58:538-45.
• [6]Amin J, Law MG, Bartlett M, Kaldor JM, Dore GJ. Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. Lancet. 2006; 368:938-45.
• [7]Crockett SD, Keeffe EB. Natural history and treatment of hepatitis B virus and hepatitis C virus coinfection. Ann Clin Microbiol Antimicrob. 2005; 4:13. BioMed Central Full Text
• [8]Yu ML, Lee CM, Chen CL, Chuang WL, Lu SN, Liu CH et al.. Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up. Hepatology. 2013; 57:2135-42.
• [9]Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009; 50:661-2.
• [10]Galban-García E1, Vega-Sanchez H, Gra-Oramas B, Jorge-Riaño JL, Soneiras-Perez M, Haedo-Castro D et al.. Efficacy of ribavirin in patients with chronic hepatitis B. J Gastroenterol. 2000; 35:347-52.
• [11]Siddiqui F, Mutchnick M, Kinzie J, Peleman R, Naylor P, Ehrinpreis M. Prevalence of hepatitis A virus and hepatitis B virus immunity in patients with polymerase chain reaction-confirmed hepatitis C: implications for vaccination strategy. Am J Gastroenterol. 2001; 96:858-63.